Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 16;24(8):7344.
doi: 10.3390/ijms24087344.

Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends

Alessandro Posa  1 , Andrea Contegiacomo  1 , Francesca Romana Ponziani  2   3 , Ernesto Punzi  1 , Giulia Mazza  1 , Annarita Scrofani  1 , Maurizio Pompili  2   3 , Shraga Nahum Goldberg  4 , Luigi Natale  1   3 , Antonio Gasbarrini  2   3 , Evis Sala  1   3 , Roberto Iezzi  1   3
Affiliations
Review

Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends

Alessandro Posa et al. Int J Mol Sci. .

Abstract

Personalized cancer treatments help to deliver tailored and biologically driven therapies for cancer patients. Interventional oncology techniques are able to treat malignancies in a locoregional fashion, with a variety of mechanisms of action leading to tumor necrosis. Tumor destruction determines a great availability of tumor antigens that can be recognized by the immune system, potentially triggering an immune response. The advent of immunotherapy in cancer care, with the introduction of specific immune checkpoint inhibitors, has led to the investigation of the synergy of these drugs when used in combination with interventional oncology treatments. The aim of this paper is to review the most recent advances in the field of interventional oncology locoregional treatments and their interactions with immunotherapy.

Keywords: ablation; immune checkpoint inhibitors; immunotherapy; interventional oncology; personalized medicine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Interventional oncology ablative and endovascular techniques and mode of action. IRE: irreversible electroporation; RFA: radiofrequency ablation; MWA: microwave ablation; TACE: transcatheter arterial chemoembolization; TARE: transcatheter arterial radioembolization.
See this image and copyright information in PMC

References

    1. Erinjeri J.P., Fine G.C., Adema G.J., Ahmed M., Chapiro J., Brok M.D., Duran R., Hunt S.J., Johnson D.T., Ricke J., et al. Immunotherapy and the Interventional Oncologist: Challenges and Opportunities—A Society of Interventional Oncology White Paper. Radiology. 2019;292:25–34. doi: 10.1148/radiol.2019182326. - DOI - PMC - PubMed
    1. Helmberger T. The evolution of interventional oncology in the 21st century. Br. J. Radiol. 2020;93:20200112. doi: 10.1259/bjr.20200112. - DOI - PMC - PubMed
    1. Reig M., Forner A., Rimola J., Ferrer-Fàbrega J., Burrel M., Garcia-Criado Á., Kelley R.K., Galle P.R., Mazzaferro V., Salem R., et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system: The 2022 update. J. Hepatol. 2021;76:681–693. doi: 10.1016/j.jhep.2021.11.018. - DOI - PMC - PubMed
    1. Campbell S.C., Clark P.E., Chang S.S., Karam J.A., Souter L., Uzzo R.G. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J. Urol. 2021;206:199–208. doi: 10.1097/JU.0000000000001911. - DOI - PubMed
    1. Campbell S.C., Uzzo R.G., Karam J.A., Chang S.S., Clark P.E., Souter L. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-up: AUA Guideline: Part II. J. Urol. 2021;206:209–218. doi: 10.1097/JU.0000000000001912. - DOI - PubMed